HSP90AA1 and COVID-19: As observed in Calu-3 cells, chemical inhibition of HSP90 in infected human primary cells reduced viral replication and the induction of the inflammatory response, suggesting that 17-AAG or other HSP90 inhibitors already applied in clinical trials could be used for the therapeutic interventions in the treatment of COVID-19.